Looking for:
Prednisone effect on kidneys |
Prednisone effect on kidneys. Effect of prednisone on renal function in man
Prednisone - NephCure Kidney International ® - Introduction
IgA nephropathy is a disease where the kidney is damaged by the immune system when the antibody immunoglobulin A IgA lodges in the kidneys. Up to 30 percent of all people with IgA nephropathy will eventually develop kidney failure requiring dialysis or kidney transplantation to prevent death.
Although IgAN has no proven specific treatment, steroids are commonly used around the world to try to treat the condition, as they supress the immune system, a number of small studies suggest they might have some benefits, and they are relatively affordable. As a result, clinical guidelines currently recommend corticosteroids should be considered for patients with IgA nephropathy and persistent proteinuria.
Read the full paper in the Journal of the American Medical Association. IT SC CS Kaplan—Meier analysis revealed that renal survival during the follow-up period was significantly better in the CS group at 36, 60, and 80 months It is worth noting that the survival curve of the CS group remained stable for about 52 months and then decreased rapidly thereafter, whereas survival curve of the IT group decreased rapidly in the beginning and became relatively stable after 52 months.
At the end of the follow-up period, the survival curve in the CS and IT groups almost overlapped. Figure 2. Renal survival of stage 1 CKD patients was relatively good regardless of the different treatment regimens Figure 3B. These results suggest that optimal supportive care may be the best choice for patients with moderate stage IgAN.
Figure 3. Kaplan—Meier analysis for the probability of composite end point in different CKD stages. A Kidney survival rates in CKD stage 1, 2, and 3a groups.
These clinical and morphology data determined that these patients should be treated with steroids. Table 3. Subgroup analysis of clinical and morphology data for the probability of composite end point by Kaplan-Meier analysis. The correlations between clinicopathological parameters and renal end point were analyzed using a Cox regression model Table 4. A multivariate Cox regression analysis further showed that hypertension HR 1.
Table 4. Cox proportional hazard model for the primary end point in IgA nephropathy patients. Previous studies of treatments for IgAN patients have yielded discordant results.
Currently, RASI, corticosteroids, and immunosuppressive therapy are commonly used in clinical practice. Although the KDIGO guidelines provide general recommendations for the treatment of IgAN, the guidelines do not take pathological changes and ethnic differences into account 3 , 7. Indeed, it is difficult to remain completely consistent with the guidelines in clinical practice. Due to the various individual clinicopathological characteristics of patients and the possibility of severe adverse events, the treatment plans chosen by doctors and patients are often different.
There are currently no large clinical trials underway to evaluate the efficacy of different treatments for early-stage IgAN patients. Some studies have found that the addition of immunosuppressive therapy in treatment plans for IgAN patients did not significantly improve renal outcome, while several other studies have suggested the opposite 4 , 5 , 8 , 9.
Thus, further studies with large sample sizes and long-term follow-up are critically needed to estimate the effects of different treatment regimens and predict the best therapeutic regimens.
In this study, we enrolled patients from four study centers and followed up for Steroid treatment was better than added immunosuppressant therapy or supportive care along in achieving CR These results provide new evidence for the use of corticosteroids alone in patients with early-stage IgAN.
Currently, corticosteroid use in patients with IgAN is inconsistent, and it is difficult to summarize a personalized treatment 7. However, the evidence supporting this guideline is low level 2C 3. RASBs alone 4 , 8. However, several other studies found that the use of corticosteroids improved outcomes compared with control groups 5 , 9 , especially in Asian patients. These clinical and morphology data support the idea that these patients should be treated with steroids.
It was important to note that the survival curve of the CS group remained almost stable for about 52 months before decreasing rapidly thereafter. These results indicate that the short-term effects of corticosteroids are better than the long-term effects.
One possible mechanism for this might be that the early application of steroids can inhibit inflammation, immune responses, and fibrosis of the kidney, resulting in improved renal prognosis. Nevertheless, the reactivation of inflammation and immune responding after cessation of the steroid treatment could subsequently lead to poorer long-term prognosis.
Further research is needed to confirm this hypothesis. Though the KDIGO guidelines does not currently recommend immunosuppressive therapies for IgAN patients, they are sometimes used in clinical practice for patients with high-risk and active pathological changes. Immunosuppressive drugs are used to modulate the immune response, inhibit inflammation, relieve fibrosis and mesangial proliferation, and reduce levels of galactose-deficient IgA1 However, the use of immunosuppressant drugs for IgAN is in dispute due to the difficulty in balancing between toxicity and long-term renal survival Some reports found that immunosuppressants might lower proteinuria and improve renal outcome in patients with IgAN 12 , 13 , while several studies did not find prominent benefits from an immunosuppressive combination protocol 14 , Our study indicated that renal survival was significantly better in the CS group than in the IT group during the follow-up period.
More severe clinical manifestations lower eGFR and higher proteinuria and pathological changes more M, S, T, and C lesions in patients in the IT group may explain why poorer renal outcome was observed more in patients in the IT group than in the CS group.
This outcome indicated that immunosuppressive therapy did not result in further benefit beyond steroids. In addition, the renal survival curve for the IT group decreased rapidly at the beginning while becoming relatively stable after 52 months, which suggests that immunosuppressants may be beneficial for long-term renal survival in IgAN patients.
However, these findings must be validated by further study. Results from the current study showed that the effect of treatment was largely dependent on patients' baseline eGFR levels. In stage 1 CKD patients, renal survival was considerable despite the different treatment regimens. This finding is in line with previous reports 12 that corticosteroids or immunosuppressants could only improve short-term renal outcome for advanced-stage IgAN patients.
Based on the current findings, we recommend that treatment of IgAN should be initiated as early as possible. These results are similar to previous reports 12 , Although several reports 17 have shown that patients with cellular or fibrocellular crescents have worse prognoses, crescents were not found to be associated with renal survival in the current study.
This may be due to differences in the inclusion criteria between the studies. It is clear that large-sample clinical trials are needed before conclusions can be drawn. Previous studies have also shown that the amount of proteinuria is an established risk factor in IgAN 18 , but proteinuria was not identified as a significant risk factor even in the univariate analysis in this study. Although we reported several interesting and novel results in this study, there are study limitations that should be noted.
First, this is a retrospective, single ethnicity Chinese Han study. We have to admit that the baseline characters of patients in different groups were not matched in this study. The underlying reason of this difference may be the treatment choice of doctor. Doctors tend to choose more aggressive treatment corticosteroids or immunosuppressants in patients with severer clinical and pathological features.
Therefore, this observational study could only reflect the exact effect of different treatment in real clinical practice environment, so results from this study may not be generalizable to patients from other regions of the world. A well-designed controlled study may provide more information. Second, the follow-up period was relatively short. Considering that IgAN is a slow progressive disease, a much longer follow-up period more than 10 years may be needed to reach more credible conclusions.
No other severe adverse effects were recorded. It seems that most IgAN patients were tolerable to corticosteroids and immunosuppressive therapy. No more severe adverse event was reported by patients. Most of the patients could not remember minor or moderate adverse events when we collect information from them. Therefore, further large-scale, multicenter studies with long-term follow-up and more detailed clinical and pathological data should be undertaken to provide more scientific justification for the best treatment plans for patients with IgAN.
Immunosuppressive therapy does not have further benefit beyond that provided by steroids. Corticosteroids plus optimal supportive care may further be beneficial in treating early-stage IgAN patients in that there is significant improvement of the short-term renal outcome. The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
All authors contributed to the article and approved the submitted version. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
IgA nephropathy.
❾-50%}Prednisone - Uses, side effects, dosage | National Kidney Foundation - Social links Global
Up to 30 percent of all people with IgA nephropathy will eventually develop kidney failure requiring dialysis or kidney transplantation to prevent death. Although IgAN has no proven specific treatment, steroids are commonly used around the world to try to treat the condition, as they supress the immune system, a number of small studies suggest they might have some benefits, and they are relatively affordable.
Patients prescribed prednisone should take it exactly as directed by their physicians. Using the medication as directed may help decrease the risk of potentially serious side effects and speed up recovery time. The dosage will be different for different patients.
Most doctors recommend taking prednisone at the same time each day. Taking this medicine with food or milk can help prevent stomach irritation. You should swallow the delayed-release tablet whole.
Do not crush, break, or chew it. If prescribed the oral liquid prednisolone , measure the proper dose with a marked measuring spoon, oral syringe, or medicine cup.
The average household teaspoon may not hold the right amount of liquid. Measure the concentrated liquid with the special oral dropper that comes with the package. If you take prednisone for a long time, do NOT stop using it suddenly without talking to your doctor first.
You may need to decrease your dose slowly before stopping it completely to prevent withdrawal symptoms. Prednisone tapering is a gradual reduction in the dosage to reduce or avoid symptoms of withdrawal.
Doses will start higher and drop over several days, weeks, or months so the body can adjust to the reduction. This practice is considered a necessary part of therapy if patients have taken prednisone for more than two weeks. One of the biggest concerns in using prednisone is that the body responds in ways that foster dependency on it. This occurs because of a chemical similarity between the manufactured hormone and cortisol, a hormone that humans produce naturally.
The presence of prednisone sends a signal to the adrenal system to stop making cortisol. When the prednisone is abruptly withdrawn, the body is suddenly without optimum cortisol levels — this can lead to adrenal suppression, a potentially serious condition.
It is usually given as a pill when used after a kidney transplant , or for certain kidney disorders. Steroid drugs, such as prednisone, work by lowering the activity of the immune system. Prednisone can help lower certain immune-related symptoms, including inflammation and swelling. The body recognizes a transplanted organ as a foreign mass.
These conditions can lead to nephrotic syndrome. As a result, large amounts of protein leaks into the urine. This in turn reduces the amount of protein in your blood, known as proteinuria.
Prednisone is used to help lower proteinuria in these disorders. People taking prednisone can also experience higher blood sugar, which is a special concern for those with diabetes. These results are similar to previous reports 12 , Although several reports 17 have shown that patients with cellular or fibrocellular crescents have worse prognoses, crescents were not found to be associated with renal survival in the current study.
This may be due to differences in the inclusion criteria between the studies. It is clear that large-sample clinical trials are needed before conclusions can be drawn. Previous studies have also shown that the amount of proteinuria is an established risk factor in IgAN 18 , but proteinuria was not identified as a significant risk factor even in the univariate analysis in this study.
Although we reported several interesting and novel results in this study, there are study limitations that should be noted. First, this is a retrospective, single ethnicity Chinese Han study. We have to admit that the baseline characters of patients in different groups were not matched in this study. The underlying reason of this difference may be the treatment choice of doctor. Doctors tend to choose more aggressive treatment corticosteroids or immunosuppressants in patients with severer clinical and pathological features.
Therefore, this observational study could only reflect the exact effect of different treatment in real clinical practice environment, so results from this study may not be generalizable to patients from other regions of the world.
A well-designed controlled study may provide more information. Second, the follow-up period was relatively short.
Considering that IgAN is a slow progressive disease, a much longer follow-up period more than 10 years may be needed to reach more credible conclusions. No other severe adverse effects were recorded. It seems that most IgAN patients were tolerable to corticosteroids and immunosuppressive therapy. No more severe adverse event was reported by patients.
Most of the patients could not remember minor or moderate adverse events when we collect information from them. Therefore, further large-scale, multicenter studies with long-term follow-up and more detailed clinical and pathological data should be undertaken to provide more scientific justification for the best treatment plans for patients with IgAN.
Immunosuppressive therapy does not have further benefit beyond that provided by steroids. Corticosteroids plus optimal supportive care may further be beneficial in treating early-stage IgAN patients in that there is significant improvement of the short-term renal outcome. The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
All authors contributed to the article and approved the submitted version. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
IgA nephropathy. N Engl J Med. Coppo R. Corticosteroids in IgA nephropathy: lessons from recent studies. J Am Soc Nephrol. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. Intensive supportive care plus immunosuppression in IgA nephropathy. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. Ponticelli C, Locatelli F. Corticosteroids in IgA nephropathy.
Am J Kidney Dis. Pozzi C. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.
Background: The efficacy and safety of corticosteroids and immunosuppressive therapy remain controversial for the treatment of immunoglobulin A nephropathy IgAN. Methods: Patients with biopsy-proven IgAN were retrospectively enrolled from four study centers between and Patients were regularly followed up for at least 1 year or until the study end point.
Patients were categorized into three treatment groups: supportive care SCsteroids alone CSand steroids plus immunosuppressants IT. The observed CR rate was Renal outcomes were remarkably better in the CS group compared with the SC and IT groups the percentage of patients reaching the end point in each group was 4.
Moreover, 36 and month renal survival were significantly better for the CS group Renal survival of CKD stage 1 patients was relatively good regardless of the specific treatment regimen.
However, renal survival of CKD stage 3a patients was not impacted by any of the three treatment regimens. Conclusions: Immunosuppressive therapy does not have further benefit beyond that provided by steroids.
Corticosteroids plus optimal supportive care may further be beneficial in treating early-stage IgAN patients in that it could significantly improve the short-term renal outcome. It is characterized by the presence of IgA immune complex deposits in the mesangium of kidney 1. The best treatment plan for IgAN patients is still controversial. However, several trials have shown discordant results for this treatment plan.
Others have reported that corticosteroids and immunosuppressive treatment can improve short-term renal outcome in advanced-stage IgAN patients, but not their long-term prognosis 5. All patients were followed for at least 12 months or until the study reached its pre-defined end point.
Treatment was chosen according to patients' willingness and doctors' experience. Written informed consent was obtained from all patients. However, the role for corticosteroids is limited to cases with minimal change on light microscopy in IgAN with nephrotic syndrome, or glomerular filtration rate is impaired severely or there are pathologic features of chronic injury in crescentic IgAN. Since there were no standard treatment guidelines for patients presented with significantly heterogeneous clinical and pathological manifestation, therapeutic regimens were determined by both the doctors' experience and the patients' willing based on current consensus.
Adverse drug events were carefully described to each patient. Patients were given optimal supportive therapy if they refused to take steroids or immunosuppressants for steroid-related adverse effects. Patients were categorized into three groups according to the chosen therapy strategies. In addition, patients with tonsillectomy or those using fish oil were excluded from this study. Follow-up duration is defined as the interval between renal biopsy and the last outpatient visit, death, or ESRD.
Renal biopsies were evaluated by an experienced pathologist and a nephrologist. Categorical variables are expressed as frequencies and percentages and then were compared using Fisher and chi-squared tests. Kidney survival in each group was estimated by the Kaplan—Meier method, and survival curves were compared by the Log-rank test.
Univariate and multivariate Cox proportional hazard models were used to evaluate the influence of clinical and pathological variables on renal outcomes. The basic characteristics of the enrolled patients at baseline are shown in Table 1. Patients were followed for Of the patients, The baseline analyses indicated that patients in the IT group presented with significantly more severe clinical and pathological manifestations, such as higher Scr, lower eGFR, greater h proteinuria, higher SBP, and severe renal pathologic changes compared to patients in the SC and CS groups Table 1.
There were no significant differences among three groups in the CKD 3 stage at baseline analysis. Figure 1. Flow diagram. Table 1. Baseline clinicopathological characteristics of IgAN patients in different therapies. Following treatment, patients One patient 0. We observed that patients in the CS group patients, At the end of follow-up, 64 patients 9. Most of these patients were in the SC group 21, IT SC CS Kaplan—Meier analysis revealed that renal survival during the follow-up period was significantly better in the CS group at 36, 60, and 80 months It is worth noting that the survival curve of the CS group remained stable for about 52 months and then decreased rapidly thereafter, whereas survival curve of the IT group decreased rapidly in the beginning and became relatively stable after 52 months.
At the end of the follow-up period, the survival curve in the CS and IT groups almost overlapped. Figure 2. Renal survival of stage 1 CKD patients was relatively good regardless of the different treatment regimens Figure 3B.
These results suggest that optimal supportive care may be the best choice for patients with moderate stage IgAN. Figure 3. Kaplan—Meier analysis for the probability of composite end point in different CKD stages. A Kidney survival rates in CKD stage 1, 2, and 3a groups. These clinical and morphology data determined that these patients should be treated with steroids.
Table 3. Subgroup analysis of clinical and morphology data for the probability of composite end point by Kaplan-Meier analysis. The correlations between clinicopathological parameters and renal end point were analyzed using a Cox regression model Table 4.
A multivariate Cox regression analysis further showed that hypertension HR 1. Table 4. Cox proportional hazard model for the primary end point in IgA nephropathy patients. Previous studies of treatments for IgAN patients have yielded discordant results. Currently, RASI, corticosteroids, and immunosuppressive therapy are commonly used in clinical practice.
Although the KDIGO guidelines provide general recommendations for the treatment of IgAN, the guidelines do not take pathological changes and ethnic differences into account 37. Indeed, it is difficult to remain completely consistent with the guidelines in clinical practice. Due to the various individual clinicopathological characteristics of patients and the possibility of severe adverse events, the treatment plans chosen by doctors and patients are often different.
There are currently no large clinical trials underway to evaluate the efficacy of different treatments for early-stage IgAN patients. Some studies have found that the addition of immunosuppressive therapy in treatment plans for IgAN patients did not significantly improve renal outcome, while several other studies have suggested the opposite 4589.
Thus, further studies with large sample sizes and long-term follow-up are critically needed to estimate the effects of different treatment regimens and predict the best therapeutic regimens. In this study, we enrolled patients from four study centers and followed up for Steroid treatment was better than added immunosuppressant therapy or supportive care along in achieving CR These results provide new evidence for the use of corticosteroids alone in patients with early-stage IgAN.
Currently, corticosteroid use in patients with IgAN is inconsistent, and it is difficult to summarize a personalized treatment 7. However, the evidence supporting this guideline is low level 2C 3.
RASBs alone 48. However, several other studies found that the use of corticosteroids improved outcomes compared with control groups 59especially in Asian patients. These clinical and morphology data support the idea that these patients should be treated with steroids. It was important to note that the survival curve of the CS group remained almost stable for about 52 months before decreasing rapidly thereafter.
These results indicate that the short-term effects of corticosteroids are better than the long-term effects. One possible mechanism for this might be that the early application of steroids can inhibit inflammation, immune responses, and fibrosis of the kidney, resulting in improved renal prognosis. Nevertheless, the reactivation of inflammation and immune responding after cessation of the steroid treatment could subsequently lead to poorer long-term prognosis. Further research is needed to confirm this hypothesis.
Though the KDIGO guidelines does not currently recommend immunosuppressive therapies for IgAN patients, they are sometimes used in clinical practice for patients with high-risk and active pathological changes. Immunosuppressive drugs are used to modulate the immune response, inhibit inflammation, relieve fibrosis and mesangial proliferation, and reduce levels of galactose-deficient IgA1 However, the use of immunosuppressant drugs for IgAN is in dispute due to the difficulty in balancing between toxicity and long-term renal survival Some reports found that immunosuppressants might lower proteinuria and improve renal outcome in patients with IgAN 1213while several studies did not find prominent benefits from an immunosuppressive combination protocol 14 Our study indicated that renal survival was significantly better in the CS group than in the IT group during the follow-up period.
More severe clinical manifestations lower eGFR and higher proteinuria and pathological changes more M, S, T, and C lesions in patients in the IT group may explain why poorer renal outcome was observed more in patients in the IT group than in the CS group. This outcome indicated that immunosuppressive therapy did not result in further benefit beyond steroids.
In addition, the renal survival curve for the IT group decreased rapidly at the beginning while becoming relatively stable after 52 months, which suggests that immunosuppressants may be beneficial for long-term renal survival in IgAN patients. However, these findings must be validated by further study.
Results from the current study showed that the effect of treatment was largely dependent on patients' baseline eGFR levels. In stage 1 CKD patients, renal survival was considerable despite the different treatment regimens. This finding is in line with previous reports 12 that corticosteroids or immunosuppressants could only improve short-term renal outcome for advanced-stage IgAN patients. Based on the current findings, we recommend that treatment of IgAN should be initiated as early as possible.
These results are similar to previous reports 12 Although several reports 17 have shown that patients with cellular or fibrocellular crescents have worse prognoses, crescents were not found to be associated with renal survival in the current study. This may be due to differences in the inclusion criteria between the studies.
This study shows that prednisolone decreases inflammation and improves renal function, whilst not reducing liver injury. The persistence of. Prednisone can help prevent organ rejection after a kidney transplant because of its ability to suppress the immune system. This study shows that prednisolone decreases inflammation and improves renal function, whilst not reducing liver injury. The persistence of. These results indicate that the short-term effects of corticosteroids are better than the long-term effects. One possible mechanism for this. Prednisone will decrease the inflammation in your kidneys so they can function less active before the inflammation leads to permanent kidney damage. Give the gift of hope. You might also get the infection the vaccine is meant to prevent. Subgroup analysis of clinical and morphology data for the probability of composite end point by Kaplan-Meier analysis.Prednisone is a prescription drug. This means your healthcare provider has given it to you as part of a treatment plan. Prednisone is part of a group of drugs called corticosteroids often called "steroids". Other steroid drugs include prednisolone, hydrocortisone, and methylprednisolone. Prednisone can be given in different ways, including pill, injection, and inhaled. It is usually given as a pill when used after a kidney transplant , or for certain kidney disorders. Steroid drugs, such as prednisone, work by lowering the activity of the immune system.
Prednisone can help lower certain immune-related symptoms, including inflammation and swelling. The body recognizes a transplanted organ as a foreign mass. These conditions can lead to nephrotic syndrome. As a result, large amounts of protein leaks into the urine. This in turn reduces the amount of protein in your blood, known as proteinuria. Prednisone is used to help lower proteinuria in these disorders. People taking prednisone can also experience higher blood sugar, which is a special concern for those with diabetes.
Therefore, some precautions need to be taken. Your healthcare provider will weigh the possible benefits and side effects when giving this and other medications.
Many people have benefitted from prednisone without serious side effects. Talking to your healthcare provider, using your medication as instructed, and taking the necessary precautions, can help you benefit from prednisone while managing side effects.
Here are some things you can do to keep yourself healthy:. Help patients thrive with your Giving Tuesday gift. Skip to main content. September 23, , pm EDT. What is prednisone? How does it work? What is prednisone used for?
What are the side effects of prednisone? However, prednisone also has possible side effects. These may include: Headaches Changes in mood Slowed healing of cuts and bruises Acne Fatigue Dizziness Changes in appetite Weight gain Swelling face, arms, hands, lower legs, or feet Can prednisone worsen other health conditions?
Before taking prednisone, talk to your healthcare provider about the following: If you have a history of allergies to prednisone or other steroid drugs Other medications you are currently taking If you have diabetes Whether you have high blood pressure If you are pregnant or planning to get pregnant What can I do to stay healthy while taking prednisone?
Here are some things you can do to keep yourself healthy: Take your medication as prescribed. Avoid double dosing. Find out from your healthcare provider what to do if you miss a dose. Usually your dose of prednisone is tapered or slowly reduced , to help avoid the effects of withdrawal. A sudden stoppage of using prednisone can lead to withdrawal symptoms including: Fatigue Dramatic changes in mood Reduce the amount salt and sugar in your diet.
Monitor your weight. Donate Now.
No comments:
Post a Comment